Medinox and Logical Therapeutics have reported positive results for Naproxen Prodrug. LT-NS001 is a novel patented NCE prodrug of the non-steroidal anti-inflammatory drug (NSAID) naproxen.
The drug is being developed to reduce the GI safety risks, including the formation of ulcers, associated with naproxen.
The trial consisted of a double-blind, randomised, active comparator study of LT-NS001 (formerly MX-1094) vs naproxen in patients aged 45 to 70 years.
During the trial, the patients underwent upper endoscopies at baseline and on day seven. The data showed patients receiving LT-NS001 experienced statistically fewer endoscopically confirmed gastric ulcers compared to subjects receiving naproxen.
The company reported no serious adverse events and LT-NS001 was well tolerated.